Question 1

What is your typical MOQ for a new OEM/ODM project?

Accepted Answer

MOQ depends on formula complexity, packaging format, and launch region. We usually define a practical pilot quantity first, then confirm commercial MOQ after validation.

Question 2

Can we request a sample kit before starting development?

Accepted Answer

Yes. We provide sample kits and technical references to help brand teams evaluate format, texture range, and quality direction before formal project kickoff.

Question 3

Do you support both OEM and ODM collaboration models?

Accepted Answer

Yes. We support OEM execution based on your formula direction and ODM collaboration where we co-develop formula and manufacturing strategy according to your brand goals.

Question 4

How long does a typical single-dose project take?

Accepted Answer

Timeline varies by formula and compliance scope. A practical path includes requirement alignment, sample stage, pilot validation, and commercial onboarding.

Question 5

Can you work with an existing formula from our brand or lab?

Accepted Answer

Yes. We can review an existing formula for filling-path fit, packaging compatibility, stability needs, and transfer readiness before confirming whether it is suitable for a single-dose manufacturing route.

Question 6

Can you support preservative-conscious or preservative-free concepts?

Accepted Answer

Project feasibility depends on formula system and claim strategy. We evaluate stability, packaging fit, and quality controls before confirming final claim direction.

Question 7

What single-dose packaging formats or fill sizes can be evaluated?

Accepted Answer

Format and fill-size options depend on formula viscosity, dose target, opening experience, secondary packaging, and commercial volume. Early evaluation should align formula behavior with packaging and user-flow requirements.

Question 8

Do you support pilot runs before commercial scale-up?

Accepted Answer

Yes. A pilot run can help confirm formula transfer, packaging behavior, quality checkpoints, and launch assumptions before a team commits to a larger commercial order.

Question 9

What should we confirm before requesting a formal quotation?

Accepted Answer

A useful quotation normally needs product type, formula status, target fill volume, packaging expectations, launch market, annual or first-order volume estimate, timeline, and any documentation requirements. If some items are uncertain, we can start with scenario planning instead of a final quote.

Question 10

How do you evaluate whether an existing formula can transfer into single-dose packaging?

Accepted Answer

We review viscosity, active sensitivity, filling temperature limits, packaging compatibility, target dose, appearance standards, and expected shelf-life work. Some formulas can transfer directly, while others need adjustment before pilot validation.

Question 11

Can you give a fixed MOQ before formula and packaging review?

Accepted Answer

Usually not responsibly. MOQ depends on packaging format, material setup, formula behavior, validation needs, and commercial plan. We can provide a planning range early, then narrow it after feasibility and pilot assumptions are clearer.

Question 12

What quality checkpoints are included before mass production?

Accepted Answer

Typical checkpoints include raw material verification, process control validation, packaging integrity checks, visual standards, and release criteria alignment.

Question 13

Can you provide documentation for quality or export review?

Accepted Answer

Documentation support depends on the project scope and target market. We can discuss quality-system references, production documentation, and export coordination needs during project scoping.

Question 14

Do you sign NDAs for confidential OEM/ODM projects?

Accepted Answer

Yes. For confidential formula, brand, or launch discussions, NDA handling can be part of the early scoping process before detailed technical information is exchanged.

Question 15

What should brand teams expect after submitting a project brief?

Accepted Answer

The next step is usually a fit review covering formula direction, target format, market requirements, pilot readiness, and expected decision gates. If the project is a fit, the team can move into sampling, feasibility review, or a more detailed quotation path.

Question 16

Do you support custom packaging and branding requirements?

Accepted Answer

Yes. We can align filling and packaging plans with your branding requirements, subject to technical compatibility and production feasibility.

Question 17

Can international brands work with your team directly?

Accepted Answer

Yes. We support global brand teams with structured communication, project milestones, and documentation coordination for cross-border collaboration.

Question 18

What information helps your team evaluate project fit faster?

Accepted Answer

Helpful information includes product type, target market, formula status, intended claims, target fill volume, launch timeline, expected MOQ range, and whether the product is for retail, medspa, or post-procedure use.

Question 19

What information should we prepare before contacting your team?

Accepted Answer

Please prepare target market, product positioning, expected volume, timeline goals, and any initial formula or claim requirements.

Question 20

How do we start a consultation?

Accepted Answer

You can submit your project brief through the contact page. Our team will review the request and respond with suggested next steps.

Question 21

How is MOQ structured across pilot runs and commercial scale-up batches?

Accepted Answer

We use a tiered approach: a pilot MOQ for initial formula validation, packaging-fit testing, and stability work, then a separate commercial MOQ confirmed after pilot results and volume projections are clearer. This avoids committing to full-scale batch sizes before feasibility is established.

Question 22

What is the typical lead time for sample kits and stability testing batches?

Accepted Answer

Sample kit lead time depends on formula complexity and packaging setup, typically 3-6 weeks after brief alignment. Stability testing batches require additional lead time for controlled production and monitoring setup. Early scheduling during the scoping phase helps align sample delivery with your development calendar.

Question 23

Can an existing preservative-based formula be adapted for a preservative-free single-dose vial?

Accepted Answer

It depends on the formula system. We review the existing formula for viscosity, active sensitivity, thermal tolerance, and packaging compatibility. Some formulas can transition with minor adjustments; others may need reformulation work to maintain stability without a conventional preservative system. The review also considers whether the single-dose format's reduced repeated-open exposure is sufficient to support the target claim.

Question 24

At what stage do you initiate an NDA for confidential discussions?

Accepted Answer

NDA handling is typically initiated during early scoping, before any detailed formula, brand, or launch information is exchanged. We keep the process straightforward so that technical discussions are not delayed by administrative steps.

Question 25

What export documentation and quality compliance scenarios do you typically support?

Accepted Answer

Documentation support varies by target market and project scope. Common scenarios include certificate of analysis and manufacturing batch records, stability study summaries, GMPC and ISO 22716 quality-system references, ingredient and packaging compliance documentation for CN, US FDA, EU, GCC, and ASEAN review, and labeling and claim-support documentation aligned with local regulatory expectations. Specific requirements should be confirmed during project scoping.

Operational Standards and FAQ for Sterile Single-Dose Projects